Results 21 to 30 of about 21,698 (162)

Mutations in Efflux Pump Rv1258c (Tap) Cause Resistance to Pyrazinamide, Isoniazid, and Streptomycin in M. tuberculosis

Frontiers in Microbiology, 2019
Although drug resistance in Mycobacterium tuberculosis is mainly caused by mutations in drug activating enzymes or drug targets, there is increasing interest in the possible role of efflux in causing drug resistance.
Jiayun Liu, Jiayun Liu, Wanliang Shi, Shuo Zhang, Xiaoke Hao, Dmitry A. Maslov, Kirill V. Shur, Olga B. Bekker, Valery N. Danilenko, Ying Zhang   +9 more
doaj   +1 more source

New Potentially Active Pyrazinamide Derivatives Synthesized Under Microwave Conditions

Molecules, 2014
A series of 18 N-alkyl substituted 3-aminopyrazine-2-carboxamides was prepared in this work according to previously experimentally set and proven conditions using microwave assisted synthesis methodology.
Ondrej Jandourek, Martin Dolezal, Jiri Kunes, Vladimir Kubicek, Pavla Paterova, Matus Pesko, Vladimir Buchta, Katarina Kralova, Jan Zitko   +8 more
doaj   +1 more source

Correlations among the plasma concentrations of first-line anti-tuberculosis drugs and the physiological parameters influencing concentrations

Frontiers in Pharmacology, 2023
Background: The plasma concentrations of the four most commonly used first-line anti-tuberculosis (TB) drugs, isoniazid (INH), rifampicin (RMP), ethambutol (EMB), and pyrazinamide (PZA), are often not within the therapeutic range.
Lin Cheng, Ming Luo, Yan Guo, Yunfan Fan, Pengsen Wang, Gang Zhou, Shiwei Qin, Bangbi Weng, Peibo Li, Zhirui Liu, Songtao Liu   +10 more
doaj   +1 more source

Structure-Aware Mycobacterium tuberculosis Functional Annotation Uncloaks Resistance, Metabolic, and Virulence Genes

mSystems, 2021
Accurate and timely functional genome annotation is essential for translating basic pathogen research into clinically impactful advances. Here, through literature curation and structure-function inference, we systematically update the functional genome ...
Samuel J. Modlin, Afif Elghraoui, Deepika Gunasekaran, Alyssa M. Zlotnicki, Nicholas A. Dillon, Nermeeta Dhillon, Norman Kuo, Cassidy Robinhold, Carmela K. Chan, Anthony D. Baughn, Faramarz Valafar   +10 more
doaj   +1 more source

Pyrazinamide Induced Polyarthralgia and Myalgia in a Case of Pulmonary Tuberculosis – A Case Report [PDF]

Journal of Krishna Institute of Medical Sciences University, 2021
Pyrazinamide Induced polyarthralgia is common but myalgia is an uncommon adverse drug reaction. Understanding a case with estimated peak plasma concentration correlation is very rarely performed.
Bijoy Kumar Panda, Vaibhav Rajendra Suryawanshi, Aksa Thomas, Medha Bargaje, Sathiyanarayanan L   +4 more
doaj  

Precipitation of Zn(II)-Pyrazinamide Complex from Ethanol Solution as an Antibacterial Candidate based on Transitional Metal Complex Compounds

Indonesian Green Technology Journal
The Zn(II)-pyrazinamide complex compound is currently being developed as an antibacterial agent. To obtain the Zn(II)-pyrazinamide complex effectively, many factors must be considered, including the type of zinc(II) salt and the mole ratio.
Naila Azmi Adiba, Danar Purwonugroho, Yuniar Ponco Prananto   +2 more
doaj   +1 more source

Genetic Diversity and Drug Susceptibility Profiles of Multidrug-Resistant Tuberculosis Strains in Southeast China

Infection and Drug Resistance, 2021
Shufang Lin,1 Shuzhen Wei,1 Yong Zhao,1 Zhisong Dai,1 Jian Lin,1 Yu Pang2 1Fujian Provincial Key Laboratory of Zoonosis Research, Fujian Center for Disease Control and Prevention, Fuzhou, People’s Republic of China; 2Department of Bacteriology and ...
Lin S, Wei S, Zhao Y, Dai Z, Lin J, Pang Y   +5 more
doaj  

Characterization of pyrazinamide resistance in consecutive multidrug-resistant mycobacterium tuberculosis isolates in sweden between 2003 and 2015

International Journal of Mycobacteriology, 2017
Background: The first line anti-tuberculosis drug pyrazinamide (PZA) is important when treating PZA susceptible multidrug-resistant tuberculosis (MDR-TB). Several drug resistance surveys have however reported PZA resistance among a significant proportion
Mikael Mansjo, Jim Werngren, Sven Hoffner   +2 more
doaj   +1 more source

Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies

Medicinal Research Reviews, EarlyView.
ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva, Alessandra Aiello, Tonino Alonzi, M. Alice Carvalho, Vladimir Finger, Delia Goletti, Sven Hoffner, Yousra Kherabi, Jan Korabecny, Julia Kulczyńska, Agnieszka Kyzioł, Alicia Lacoma, Filomena Martins, Zorica Nanovic, Sepideh Hosseiniporgham, Martina Hrast Rambaher, Leonardo Antonio Sechi, Daria Smalchuk, Grażyna Stochel, Lydia Tabernero, Nancy L. Tateosian, Violeta Valcheva, Anamarija Zega, Mafalda Sarraguça   +23 more
wiley   +1 more source

Designing molecular diagnostics for current tuberculosis drug regimens

Emerging Microbes and Infections, 2023
Diagnostic development must occur in parallel with drug development to ensure the longevity of new treatment compounds. Despite an increasing number of novel and repurposed anti-tuberculosis compounds and regimens, there remains a large number of drugs ...
Sophia B. Georghiou, Margaretha de Vos, Kavindhran Velen, Paolo Miotto, Rebecca E. Colman, Daniela Maria Cirillo, Nazir Ismail, Timothy C. Rodwell, Anita Suresh, Morten Ruhwald   +9 more
doaj   +1 more source